Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Toxicol ; 38(3): 173-182, 2019.
Article in English | MEDLINE | ID: mdl-30852923

ABSTRACT

Fulranumab, an anti-human nerve growth factor antibody, was evaluated in a series of nonclinical toxicology studies. No treatment effects were observed in adolescent cynomolgus monkeys in standard design, repeat-dose toxicology studies of up to 6 months. Adverse effects on the developing nervous system were observed in offspring of pregnant cynomolgus monkeys treated with fulranumab. Subsequent studies including detailed morphologic investigations of the nervous system did reveal fulranumab-related changes in adult cynomolgus monkeys; this article is focused on those findings. A single dose of ≥1 mg/kg fulranumab administered subcutaneously (SC) caused a decrease in neuron and sympathetic ganglion size (superior cervical ganglion), observed morphologically and stereologically, with a resulting appearance of increased glial cell density. Similar results were observed in repeat-dose (15 to 52 weeks) toxicity studies at ≤50 mg/kg/wk fulranumab SC. These effects recovered after a 3-month treatment-free period. Fulranumab did not cause any neuronal death, necrosis, apoptosis, or any apparent decrease in function of sympathetic neurons/ganglia at any time point examined. A no observed effect level (NOEL) was established at 0.25 mg/kg fulranumab SC every 4 weeks for 28 weeks.


Subject(s)
Antibodies, Monoclonal, Humanized/toxicity , Nerve Growth Factor/antagonists & inhibitors , Animals , Central Nervous System/drug effects , Female , Macaca fascicularis , Male , Neurons/drug effects , No-Observed-Adverse-Effect Level , Peripheral Nervous System/drug effects , Pregnancy , Toxicity Tests, Chronic
2.
Birth Defects Res B Dev Reprod Toxicol ; 92(4): 359-80, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21770023

ABSTRACT

Evaluation of pharmaceutical agents in children is now conducted earlier in the drug development process. An important consideration for this pediatric use is how to assess and support its safety. This article is a collaborative effort of industry toxicologists to review strategies, challenges, and current practice regarding preclinical safety evaluations supporting pediatric drug development with biopharmaceuticals. Biopharmaceuticals include a diverse group of molecular, cell-based or gene therapeutics derived from biological sources or complex biotechnological processes. The principles of preclinical support of pediatric drug development for biopharmaceuticals are similar to those for small molecule pharmaceuticals and in general follow the same regulatory guidances outlined by the Food and Drug Administration and European Medicines Agency. However, many biopharmaceuticals are also inherently different, with limited species specificity or immunogenic potential which may impact the approach taken. This article discusses several key areas to aid in the support of pediatric clinical use, study design considerations for juvenile toxicity studies when they are needed, and current practices to support pediatric drug development based on surveys specifically targeting biopharmaceutical development.


Subject(s)
Animals, Laboratory/growth & development , Drug Design , Drug Evaluation, Preclinical , Drugs, Investigational , Health Services Needs and Demand , Pediatrics/legislation & jurisprudence , Toxicity Tests , Animals , Biomedical Research/legislation & jurisprudence , Child , Humans , Industry , Models, Animal
3.
Toxicol Sci ; 117(2): 493-504, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20616206

ABSTRACT

The unexpected observation of a hyperglycemic effect of some tricycle-based delta opioid receptor (DOR) agonists led to a series of studies to better understand the finding. Single administration of two novel tricyclic DOR agonists dose dependently elevated rat plasma glucose levels; 4-week toxicology studies confirmed the hyperglycemic finding and further revealed pancreatic ß-cell hypertrophy, including vacuole formation, as well as bone dysplasia and Harderian gland degeneration with regeneration. Similar diabetogenic effects were observed in dog. A review of the literature on the antiserotonergic and antihistaminergic drug cyproheptadine (CPH) and its metabolites revealed shared structural features as well as similar hyperglycemic effects to the present series of DOR agonists. To further evaluate these effects, we established an assay measuring insulin levels in the rat pancreatic ß-cell-derived RINm5F cell line, extensively used to study CPH and its metabolites. Like CPH, the initial DOR agonists studied reduced RINm5F cell insulin levels in a concentration-dependent manner. Importantly, compound DOR potency did not correlate with the insulin-reducing potency. Furthermore, the RINm5F cell insulin results correlated with the diabetogenic effect of the compounds in a 5-day mouse study. The RINm5F cell insulin assay enabled the identification of aryl-aryl-amine DOR agonists that lacked an insulin-reducing effect and did not elevate blood glucose in repeated dosing studies conducted over a suprapharmacologic dose range. Thus, not only did the RINm5F cell assay open a path for the further discovery of DOR agonists lacking diabetogenic potential but also it established a reliable, economical, and high-throughput screen for such potential, regardless of chemotype or target pharmacology. The present findings also suggest a mechanistic link between the toxicity observed here and that underlying Wolcott-Rallison Syndrome.


Subject(s)
Cyproheptadine/toxicity , Hyperglycemia/chemically induced , Insulin-Secreting Cells/drug effects , Narcotic Antagonists/toxicity , Pancreas/drug effects , Serotonin Antagonists/toxicity , Animals , Blood Glucose/analysis , Blood Glucose/drug effects , Cell Enlargement/drug effects , Cell Line, Tumor , Cyproheptadine/analogs & derivatives , Diabetes Mellitus, Type 1/metabolism , Dogs , Epiphyses/abnormalities , Epiphyses/metabolism , Female , High-Throughput Screening Assays , Hyperglycemia/metabolism , Insulin/blood , Insulin-Secreting Cells/metabolism , Insulin-Secreting Cells/pathology , Insulinoma/drug therapy , Insulinoma/metabolism , Male , Mice , Osteochondrodysplasias/metabolism , Pancreas/metabolism , Pancreas/pathology , Rats , Rats, Sprague-Dawley , Vacuoles/drug effects , Vacuoles/ultrastructure
4.
Reprod Toxicol ; 26(3-4): 220-30, 2008.
Article in English | MEDLINE | ID: mdl-18926897

ABSTRACT

Knowledge of the ontogeny of the various systems involved in distribution and elimination of drugs is important for adequate interpretation of the findings during safety studies in juvenile animals. The present study was designed to collect information on plasma concentrations of total protein and albumin, enzyme activity and mRNA expression of cytochrome P450 isoenzymes (CYP1A1/2, CYP2B1/2, CYP2E1, CYP3A1/2, and CYP4A1), carboxylesterase and thyroxin glucuronidation (T4-GT) activity in liver microsomes, and mRNA expression of transporters (Mdr1a/b, Mrp1-3 and 6, Bsep and Bcrp, Oct1-2, Oat1-3 and Oatp1a4) in liver, kidney and brain tissue during development in Sprague-Dawley rats. Enzyme activities were determined by measuring the metabolism of marker substrates; expression of mRNAs was assessed using RTq-PCR. There were considerable differences in the ontogeny of the individual cytochrome P450 isoenzymes. In addition, ontogeny patterns of enzyme activity did not always parallel ontogeny patterns of mRNA expression. Ontogeny of the transporters depended on the transporter and the organ studied. Changes in mRNA expression of the various transporters during development are likely to result in altered elimination and/or tissue distribution of substrates, with concomitant changes in hepatic metabolism, renal excretion and passage through the blood-brain barrier. Consideration of the ontogeny of metabolizing enzymes and transporters may improve the design and interpretation of results of toxicity studies in juvenile animals.


Subject(s)
ATP-Binding Cassette Transporters/analysis , Blood Proteins/analysis , Cytochrome P-450 Enzyme System/analysis , ATP-Binding Cassette Transporters/genetics , Age Factors , Animals , Animals, Newborn , Catecholamine Plasma Membrane Transport Proteins/analysis , Catecholamine Plasma Membrane Transport Proteins/genetics , Cytochrome P-450 Enzyme System/genetics , Female , Male , Microsomes, Liver/enzymology , Organic Anion Transport Protein 1/analysis , Organic Anion Transport Protein 1/genetics , Organic Anion Transporters, Sodium-Independent/analysis , Organic Anion Transporters, Sodium-Independent/genetics , Rats , Rats, Sprague-Dawley
5.
Reprod Toxicol ; 26(1): 54-5, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18514481

ABSTRACT

With the growing experience in the conduct of juvenile toxicity studies for multiple classes of compound, the 'case-by-case' approach has become under much more pressure. Instead, a general screen or 'standard design' is now commonly expected by regulatory authorities with more routine inclusion of neurological and reproductive assessments. Minor modifications or additions can be made to the design to address specific questions according to the class of drug or intended clinical use. This drift from a 'case-by-case' approach to a 'standard design' approach is present within certain reviewing divisions of the FDA, often requesting by default a rodent and non-rodent juvenile animal study. However, juvenile animal studies should be designed thoughtfully to fulfil a purpose based on scientific rationale, with each endpoint carefully considered in terms of practicality and interpretability of data generated. Only when using the appropriate strategy and design may juvenile studies add value by (1) identifying potential safety or pharmacokinetic issues for drugs intended for paediatric use, (2) suggesting additional clinical endpoints and (3) adding new information to the product label. As the knowledge from juvenile animal studies in various species grows, a better understanding of the significance/relevance of findings will be achieved.


Subject(s)
Drug Evaluation, Preclinical/methods , Drug-Related Side Effects and Adverse Reactions , Pediatrics/methods , Research Design/legislation & jurisprudence , Toxicity Tests/methods , Age Factors , Animals , Animals, Laboratory , Child , Dogs , Humans , Mice , Pharmaceutical Preparations/metabolism , Rats , United States , United States Food and Drug Administration
SELECTION OF CITATIONS
SEARCH DETAIL
...